Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | PTPRB | P23467 | 2/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873573 | 0.98 | MAOB (0.69) | MAOBAPPARPTPN2PTPN1 | |
| SCHEMBL8241837 | 0.93 | MAOB (0.63) | MAOBAPPARPTPN2PTPN1 | |
| SCHEMBL255002 | 0.91 | MAOB (0.69) | MAOBARPTPN2PTPN1PTPRB | |
| SCHEMBL16976018 | 0.84 | MAOB (0.64) | MAOBARMRGPRX4 | |
| SCHEMBL10335673 | 0.82 | MAOB (0.65) | MAOBPTPN2PTPN1PTPRBPTPN6 | |
| SCHEMBL850999 | 0.82 | APP (0.78) | MAOBAPPMAOA | |
| SCHEMBL4883457 | 0.81 | MAOB (0.72) | MAOBAPPPTPN2PTPN1PTPRB | |
| SCHEMBL11426612 | 0.81 | MAOB (0.67) | MAOBPTPN2PTPN1PTPRBPTPN6 | |
| SCHEMBL27613913 | 0.80 | MAOB (0.58) | MAOBPTPN2PTPN1PTPRBPTPN6 | |
| SCHEMBL23266730 | 0.80 | MAOB (0.70) | MAOBAPPPTPN2PTPN1PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379517-A2 | ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6548548-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020111364-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002046181-A2 | ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111364-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | MAOB 3375/4885APP 2640/4885AR 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.